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Protein kinase C @‘KC) from human promyeiocytic leukemia HL-60 cells can be resolved into three fractions (peak a, b and c) by hydroxyapatite 
coiumn ch~mato~phy. Peak a and c enzymes are indistin~i~able from the brain type II PKC having @ @I and ~I)-~~~ and type III 
having e-sequence, respectively. Peak 6 enzyme is a previously unidentified PKC subspecies that has enxymological properties ubtly different from 
type I (having y-sequence), type II and type III PKC. Upon treatment of AL-60 cells with 1 pM retinoic acid, this peak b enxyme is decreased 
dramatically within 24 h, whilst peak u enzyme (J-PKC) is increased, and peek c (c+PKC) enzyme is slightly decreased within 48 h. The result 
implies that the PKC subspecies in HL-60 cells have distinct functions during cell differentiation. 
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1. INTRODUCTION 
Protein kinase C (PKC) is a large family of proteins 
with multiple subspecies that have subtly different en- 
zymological characteristics, and this multiplicity is im- 
plicated in the diverse roles of PKC in physiological 
cellular responses to external signals (for reviews, see 
[l,Z]). Initially, four cDNA clones, dyt ,&I, &IBfE and y, 
were isolated, which are highly conserved among 
various mammalian species. PKC from the brain tissue 
is normaBy resolved into three subfractions, types I, II 
and III, upon hydroxyapatite column chromatography 
[3], which correspond to the enzymes encoded by y-, P- 
@I- plus #II-) and CY-cDNA clone, respectively [4]. 
Recently, three additional cDNA clones of PKC, 6, 6 
and 1, have been isolated from the rat brain cDNA 
library {S] (also for a review, see [l]). 
The human promyelocytic leukemia cell line HL-60 
can differentiate to many ceil types with the 
characteristics of mature myeloid cells by various com- 
pounds, such as RA, DMSO, 1,2~-dihydrox~it~in 
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D3 and TPA (for review, see [6]). Thus, this cell line 
provides a model system for studying cellular and 
molecular events involved in proliferation and differen- 
tiation. TPA appears to play a critical role in this pro- 
cess through activation of PKC [7,8]. On the other 
hand, RA does not seem to link directly with PKC, but 
is shown to increase the PKC activity prior to cell 
growth and differentiation 19, LO] w This ~o~nni~a~on 
will describe the identi~~tion and properties of PKC 
subspecies which appear in HL-50 cells subsequent to 
RA treatment. 
2. MATERIALS AND METHODS 
2.1. MaterhzIs 
The oligopeptide MBP.+-i4 (QKRPSQRSKYL), corresponding to 
the major phosphorylation site of myelin basic protein, was used as 
a phosphate acceptor specific for PKC 1111. The oligopeptide having 
pseudosubstrate 
~R~A~~~RQK~f~), PKC 
region of PKC 
is X, - has been reported to be a 
relatively specific inhibitor of PKC by House and Kemp fl21. These 
oligopeptides employed in the present stud&s were synthesized by us- 
ing au Applied Biosystems peptide synthesizer, Model 43OA, foilow- 
ed by purification by gel filtration and reverse-phase column 
chromatography. PS and DO were purchased from Serdary Research 
Laboratories. RA (type XX), arachidonic acid, TPA and [y-32P]ATP 
were obtained from Sigma, Nu-Check-Prep, Chemicals for Cancer 
Research and DuPont-New England Nuclear, respectively. Packed 
columns, TSK DEAF5SPW column (0.75 x 7.5 cm), KB hydrox- 
yap&e column (0.78 x 10 cm, Type C) and Superose 12 HR 10130 
column were purchased from Toso, Koken and Pharmacia-LKB 
Biotechnology, respectively. 
2.2. C=efl cultlue 
HL-60 cells were grown at a ceil density between 0.5-2 x 10’ 
cell/ml as suspension in RPMI 1640 media (Flow) supplemented with 
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5% fetal bovine serum (Gibco) and 2 mM glutamate at 37°C in a 
humidified 5% CO2 atmosphere. Cells in their exponential growth 
phase were used. The basal PKC activity was not altered by cell densi- 
ty over the range described above. The cell ~fferentiation was in- 
itiated by suppl~enting the media with 1 pM RA. RA was 
solubilized in DMSO. The final concentration of DMSO was less 
than O.OS%, and it did not affect the differentiation process. 
2.3. Separation and assay of PKC 
All operations were performed at 0-4°C. HL-60 cells (2 x 10’ 
cells) were suspended in 4 ml of 20 mM Tris-HCl, pH 7.5, containing 
0.25 M sucrose, 1 mM EGTA, 1 mM EDTA, 1mM 
phenylmethylsulfonyl fluoride and 0.4 mM leupeptin. The cells were 
lysed by sonication using three 15-s bursts, and centrifuged for 
30 min at 100000 x g. The supernatant was applied to a DEAE-SPW 
column, which was connected to an FPLC system (Pharmacia LKB 
Biotechnology) and equilibrated beforehand with Buffer A (20 mM 
Tris-HCl, pH 7.5, containing 0.5 mM EDTA, 0.5 mM EGTA and 
10 mM 2-mercapt~~anol). After washing the column with 20 ml 
Buffer A, PKC was eluted by increasing the concentration of NaCl 
linearly from 0 to 0.3 M in 20 ml Buffer A. The enzyme fraction was CL 10 
applied to a packed hydroxyapatite column, which was connected to 
an FPLC system and equilibrated beforehand with Buffer B (20 mM 
potassium phosphate, pH 7.5, containing 0.5 mM EGTA, 0.5 mM 5 
EDTA, 10% (v/v) glycerol and 10 mM 2-mercapt~t~ol). The col- 
umn was washed with 28 ml Buffer B, and then, the PKC subspecies 
were eluted by increasing the concentration of potassium phosphate 0 30 
linearly from 20 to 200 mM in 84 ml Buffer B at a flow rate of 
0.4 ml/min. Fractions of 1 ml each were collected. PKC was assayed 
50 IO 
Fraction Number 
with a synthetic oligopeptide, MBP4-14. 
2.4. Antibodies 
The polyclonal anti~dies, designated CKpClB-a, CKpV3o-a, 
CKpVS@I-a, CKpVS@II-a and CKpV3y-a, were prepared against the 
sequence-specific oligopeptides FARKGALRQKNVHEVKNHKF 
(type II le3) PKC, residue 20-39), LGPAGNKVISPSEDR (type III 
(CX) PKC, residue 310-324), SYTNPEFVINV (type II (#I) PKC, 
residue 661-671), SFVNSEFLKPEVKS (type II (~911) PKC, residue 
660-673) and SPIPSPSPSPTDSK (type I (r) PKC, residue 322-335), 
respectively 1131. These antibodies were purified by column 
chromatography on goat anti-rabbit IgG antibody-Sepharose. 
3. RESULTS 
3.1. rs~latio~ of PKC subspecies 
The soluble cytoplasmic fraction of HL-60 cells was 
subjected to DEAE-SPW column chromatography as 
described above. A major peak with some shoulders of 
PKC was eluted from the column at 0.12-0.15 M 
NaCl. The enzyme fraction was subjected to hydrox- 
yapatite column chromatography using an FPLC 
system. Three peaks of PKC, peak a, b and c, were 
detected (Fig. 1A). Peak a and c enzymes were eluted 
at the position corresponding to the rat brain type II 
and type III PKC, respectively, whereas peak b enzyme 
did not correspond to any of the three PKC subfrac- 
tions from the brain tissue (Fig. 1C). Co- 
chromatography of the HL-60 and brain enzymes gave 
four peaks. 
The peak a, b and c enzymes all showed an approx- 
imate molecular mass of 80 kDa as estimated by gel 
filtration analysis. Immunobiot analysis with several 
PKC subspecies-speci~c antibodies listed in section 2 
indicated that the peak a enzyme reacted with an- 
Fig. 1. Resolution of PKC subspecies of undifferentiated and 
differentiated HL-60 cells upon hydroxyapatite column 
chromatography. The PKC preparation of DEAE-.5PW column 
fraction was subjected to hydroxyapatite cofumn chromatography as 
described in section 2. An 871 aliquot of each fraction (1 ml each) 
was assayed for PKC activity with MBP+ 14 as substrate. The DEAE- 
cellulose fraction of rat brain cytoplasm was prepared as described 
[14] and subjected to hydroxyapatite column chromatography under 
the same conditions. (A, B and C) Cytoplasmic fractions of 
undiffe~ntiat~ and differentiate @days RA-treatment) HL-60 
cells and rat brain, respectively. PKC activity in the presence of 
0.3 mM CaClz, 8 fig/ml PS and 0.8 pg/ml DO (0) or in the presence 
of 0.5 mM EGTA instead of CaC12, PS and Do (0). The letters a, 
b, c, I, II and III designate the PKC fractions. 
tibodies specific to type II PKC having the p (&I plus 
PII)-sequence, and the peak c enzyme reacted with an- 
tibodies specific to type III PKC having the a-sequence. 
On the other hand, the peak b enzyme reacted with 
none of the antibodies which recognize type I, II and 
III PKC, indicating that this enzyme is a new entity of 
PKC subspecies. The enzyme did not appear to be 6-, 
E- or S-PKC because of its unique kinetic and en- 
zymological properties (see below). 
3.2. Characterization of peak b PKC 
The PKC subspecies, peak b enzyme, which was 
eluted between type II and III PKC from the hydrox- 
yapatite column, showed typical characteristics of 
PKC. The enzyme responded well to both PS and DO 
over a wide range of Ca2+ concentrations (Fig. 2). The 
enzyme was sensitive to Ca2+, and TPA could replace 
DO. Free arachidonic acid was much less active for the 
peak b enzyme (Fig. 3A). Pseudosubstrate peptide, 
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Fig. 2. Activation of PKC fractions by Ca”, PS and Do. (A, B and 
C) The fractions of peak u, peak b and peak c, respectively. Each 
fraction of enzyme was assayed with MBPd-14 as substrate at various 
CaCls concentrations in the presence of 8 pg/ml PS plus 0.8 fig/ml 
DO (o), 8 ,ug/ml PS alone (0) or 0.8 pg/ml DO alone (A). Where 
indicated by the arrow, EGTA (0.5 mM) was added instead of CaCl2. 
Results are normalized to she maximal activation obtained in the 
presence of CaCft. PS and DG. 
PKCr+3r, was less effective to this enzyme (Fig. 3B). 
Several lines of evidence indicate that the peak b en- 
zyme is most likely a previously unidentified PKC 
subspecies. It does not appear to represent a proteolytic 
or other post-translational modification of the 
previously known PKC subspecies, since none of the 
antibodies could recognize this enzyme. The PKC 
subspecies having 6-, E- or $-sequence were not sensitive 
to Ca2+ [15,16]. 
U ZOO 4U0 0 2.5 7.6 25 
Arachidonic Acid ( FM ) PKC,,.s, (FM) 
Fig. 3. Effects of arachidonic acid and pseudosubstrate peptide, 
PKC1p_31r on PKC fractions of HL-60 cells. (A) Activation of PKC 
fractions of HL-40 cells by arachidonic acid. Each fraction of the 
enzyme was assayed with MBP4--14 as substrate at various 
concentrations of arachidonic acid in the presence of 0.3 mM CaCl2. 
(B) Inhibition of PKC fractions of HL-60 cells by PKCts-31. PKC 
was assayed with MBP4--14 as substrate at various concentrations of 
PKCrp_sr in the presence of 0.3 mM CaClz, 8 pg/ml PS and 
0.8pg/ml DO. (o), (e) and (O), peak a, b and c, respectively. 
Results are normalized to the maximal activation obtained in the 
presence of CaC12 (0.3 mM), PS (8 peg/ml) and DO (0.8 pg/ml). 
-J 
Retinoic Acid Treatment 
( Days ) 
Fig. 4. PKC subspecies of HL-60 cells after RA treatment. HL-60 
cells were cultured with 1 CM RA as described in section 2 for various 
days as indicated. Then; the cytoplasmic PKC fractions of HL-60 
cells were quantitated through DEAE-SPW and hydroxyapatite 
column chromatography as described in section 2. (m), (0), (e) and 
(A), total PKC activity (peak D + peak b + peak c), peak (I activity, 
peak b activity and peak c activity, respeqtively. Results are 
normalized to the total PKC activity found at 0 day. 
3.3. PKC sMb~~cies during dl~fere~iiatio~ 
RA is well known to induce differentiation of HL-60 
cells along the myeloid pathway [6]. Under the culture 
conditions presented herein, the growth rate was 
decreased by about 50070, and more than 30% of the 
cells showed a granulocyte-like segmented nucleus 5 
days after the supplement of 1 FM RA to the culture 
medium. The HL-60 cells treated for 4 days with RA 
were harvested, and PKC subspecies were fractionated 
as described above. The elution profile of PKC given in 
Fig. IB indicates that the peak b enzyme was 
dramatically decreased within 24 h, whilst peak a en- 
zyme increased over a longer time-period at 1-2 days, 
concomitantly with a slight decrease in peak c enzyme. 
At all stages of differentiation PKC activity in the par- 
ticulate fraction was negligible, unless TPA was added. 
Fig. 4 summarizes the analysis of the PKC subspecies, 
peak a, b and c, during differentiation induced by RA. 
4. DISCUSSION 
Makowske, et al. [17] previously reported that PKC 
in HL-60 cells was resolved into three subfractions, 
which were all induced in parallel during differentiation 
after treatment with either RA or DMSO. Although 
these authors thought that the three PKC subfractions 
were type I, II and III PKC, the present biochemical 
and immunoblot analysis indicates that HL-60 cells 
have type II (~3) and III (cu) PKC and an additional 
structur~ly unknown PKC subspecies (peak b enzyme). 
The studies of our and other laboratories have shown 
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that type I (y) PKC is expressed only in the central ner- 
vous tissues and spinal cord [ 14,181. 
In contrast to the RA-induced differentiation, ex- 
posure of HL-60 cells to TPA results in the 
macrophage-like differentiation, accompanying 
phosphorylation of several endogenous proteins [7,8]. 
TPA, however, causes rapid translocation to mem- 
branes and subsequent disappearance, down- 
regulation, of PKC. Several mutant cell lines, which do 
not translocate or down-regulate PKC, do not appear 
to differentiate to macrophage-like cells in response to 
TPA [19,20]. It is suggestive that the members of the 
PKC family in HL-60 cells play different functions and 
are distinctly regulated during cell differentiation. 
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